195 related articles for article (PubMed ID: 20567002)
21. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.
Coze C; Hartmann O; Michon J; Frappaz D; Dusol F; Rubie H; Plouvier E; Leverger G; Bordigoni P; Béhar C; Beck D; Mechinaud F; Bergeron C; Plantaz D; Otten J; Zucker JM; Philip T; Bernard JL
J Clin Oncol; 1997 Dec; 15(12):3433-40. PubMed ID: 9396394
[TBL] [Abstract][Full Text] [Related]
22. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
23. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E
J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519
[TBL] [Abstract][Full Text] [Related]
26. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
[TBL] [Abstract][Full Text] [Related]
27. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
[TBL] [Abstract][Full Text] [Related]
28. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human granulocyte colony-stimulating factor infusion and/or autologous peripheral blood stem cell transplantation as a rescue for sequential high-dose combination chemotherapy: a preliminary report.
Chau WK; Lin CK; Chow MP; Wang SY; Liu JM; Ho CH; Chiu CF; Hsu HC; Tan TD; Chan WK
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Nov; 54(5):312-20. PubMed ID: 7530591
[TBL] [Abstract][Full Text] [Related]
30. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D
Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836
[TBL] [Abstract][Full Text] [Related]
32. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
[TBL] [Abstract][Full Text] [Related]
33. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
Berlanga P; Pasqualini C; Pötschger U; Sangüesa C; Castellani MR; Cañete A; Luksch R; Elliot M; Schreier G; Kropf M; Morgenstern D; Papadakis V; Ash S; Ruud E; Brock P; Wieczorek A; Kogner P; Trahair T; Ambros P; Boterberg T; Castel V; Valteau-Couanet D; Ladenstein R
Eur J Cancer; 2021 Feb; 144():1-8. PubMed ID: 33316634
[TBL] [Abstract][Full Text] [Related]
34. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
Pettengell R; Gurney H; Radford JA; Deakin DP; James R; Wilkinson PM; Kane K; Bentley J; Crowther D
Blood; 1992 Sep; 80(6):1430-6. PubMed ID: 1381626
[TBL] [Abstract][Full Text] [Related]
35. A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
Katada C; Sugawara M; Hara H; Fujii H; Nakajima TE; Ando T; Kojima T; Watanabe A; Sakamoto Y; Ishikawa H; Hosokawa A; Hamamoto Y; Muto M; Tahara M; Koizumi W
Jpn J Clin Oncol; 2021 Feb; 51(2):199-204. PubMed ID: 33147611
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
37. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
Mitchell PL; Morland B; Stevens MC; Dick G; Easlea D; Meyer LC; Pinkerton CR
J Clin Oncol; 1997 Mar; 15(3):1163-70. PubMed ID: 9060560
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
